Premium
A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non‐Hodgkin lymphoma risk
Author(s) -
Hosgood H. Dean,
Purdue Mark P.,
Wang Sophia S.,
Zheng Tongzhang,
Morton Lindsay M.,
Lan Qing,
Menashe Idan,
Zhang Yawei,
Cerhan James R.,
Grulich Andrew,
Cozen Wendy,
Yeager Meredith,
Holford Theodore R.,
Vajdic Claire M.,
Davis Scott,
Leaderer Brian,
Kricker Anne,
Schenk Maryjean,
Zahm Shelia H.,
Chatterjee Nilanjan,
Chanock Stephen J.,
Rothman Nathaniel,
Hartge Patricia,
Armstrong Bruce
Publication year - 2011
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2010.08518.x
Subject(s) - innate immune system , lymphoma , genetic variation , gene , immunity , immunology , biology , variation (astronomy) , hematology , medicine , genetics , immune system , physics , astrophysics
Summary Genetic variation in immune‐related genes may play a role in the development of non‐Hodgkin lymphoma (NHL). To test the hypothesis that innate immunity polymorphisms may be associated with NHL risk, we genotyped 144 tag single nucleotide polymorphisms (tagSNPs) capturing common genetic variation within 12 innate immunity gene regions in three independent population‐based case‐control studies (1946 cases and 1808 controls). Gene‐based analyses found IL1RN to be associated with NHL risk (minP = 0·03); specifically, IL1RN rs2637988 was associated with an increased risk of NHL (per‐allele odds ratio = 1·15, 95% confidence interval = 1·05–1·27; P trend = 0·003), which was consistent across study, subtype, and gender. FCGR2A was also associated with a decreased risk of the follicular lymphoma NHL subtype (minP = 0·03). Our findings suggest that genetic variation in IL1RN and FCGR2A may play a role in lymphomagenesis. Given that conflicting results have been reported regarding the association between IL1RN SNPs and NHL risk, a larger number of innate immunity genes with sufficient genomic coverage should be evaluated systematically across many studies.